Early cross-coronavirus reactive signatures of humoral immunity against COVID-19
Paulina Kapłonek, Chuangqi Wang, Yannic C. Bartsch, Stephanie Fischinger, Matthew J. Gorman, Kathryn Bowman, Jaewon Kang, Diana Dayal, Patrick Martin, Radosław P. Nowak, Alexandra–Chloé Villani, Ching‐Lin Hsieh, Nicole C. Charland, Anna Gonye, Irena Gushterova, Hargun K. Khanna, Thomas J. LaSalle, Kendall M. Lavin-Parsons, Brendan M. Lilley, Carl L. Lodenstein, Kasidet Manakongtreecheep, Justin Margolin, Brenna N. McKaig, Maricarmen Rojas-López, Brian C. Russo, Nihaarika Sharma, Jessica Tantivit, Molly Thomas, Moshe Sade-Feldman, Jared Feldman, Boris Jülg, Eric J. Nilles, Elon R. Musk, Anil Menon, Eric S. Fischer, Jason S. McLellan, Aaron G. Schmidt, Marcia B. Goldberg, Michael R. Filbin, Nir Hacohen, Douglas A. Lauffenburger, Galit Alter
Abstract
The introduction of vaccines has inspired hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against SARS-CoV-2, thus we profiled the earliest humoral signatures in a large cohort of acutely ill (survivors and nonsurvivors) and mild or asymptomatic individuals with COVID-19. Although a SARS-CoV-2–specific immune response evolved rapidly in survivors of COVID-19, nonsurvivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibodies. Given the conservation of S2 across β-coronaviruses, we found that the early development of SARS-CoV-2–specific immunity occurred in tandem with preexisting common β-coronavirus OC43 humoral immunity in survivors, which was also selectively expanded in individuals that develop a paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.